Ethical Issues in Schizophrenia: Considerations for Treatment and Research
By Laura B. Dunn, MD
Schizophrenia and Valproate
By Leslie Citrome, MD, MPH
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
By Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
By Robert Risinger, Marjie Hard, Peter J. Weiden
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien